NCT01861990

Valproic Acid in Childhood Progressive Brain Tumors

Valproic Acid for Children With Recurrent and Progressive Brain Tumors

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Medical University of South Carolina · Academic / Other
• Sex: All
• Age: 1 Year
• Healthy volunteers: Not accepted

Summary

The study investigates valproic acid added to radiation and temozolomide therapy (standard of care) for progressive or recurrent pediatric brain tumors.

Detailed description

Patients with progressive or recurrent pediatric brain tumors are administered valproic acid, an HDAC inhibitor, along with standard of care therapy (radiation and temozolomide) for induction therapy. Thereafter, patients will be able to continue on valproic acid and temozolomide therapy as long as the combination is well tolerated and the tumor is not progressing.

Conditions

• Pediatric Brain Tumor
• Glioma
• Anaplastic Astrocytoma
• Medulloblastoma
• Glioblastoma

Interventions

Type	Name	Description
DRUG	Valproic Acid	All participants enrolled on valproic acid arm.

Timeline

• Start date: 2013-05-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2013-05-24
• Last updated: 2015-05-22

Locations

1 site across 1 country: United States